Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Fedratinib |
Trade Name | Inrebic |
Synonyms | SAR302503|TG101348 |
Drug Descriptions |
Inrebic (fedratinib) binds and inhibits JAK2, FLT3, and RET kinases, which may inhibit cell proliferation and tumor growth (PMID: 17541402). Inrebic (fedratinib) is FDA approved for use in patients with myelofibrosis (FDA.gov). |
DrugClasses | FLT3 Inhibitor 69 JAK2 Inhibitor - ATP competitive 15 RET Inhibitor 53 |
CAS Registry Number | 936091-26-8 |
NCIT ID | C88293 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Decitabine + Fedratinib | Decitabine Fedratinib | 0 | 2 |
Enasidenib + Fedratinib | Enasidenib Fedratinib | 0 | 1 |
Fedratinib | Fedratinib | 25 | 4 |
Fedratinib + Ivosidenib | Fedratinib Ivosidenib | 0 | 1 |